References
- 1Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365: 2078–87. DOI: 10.1056/NEJMoa1110874
- 2Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 344: 1959–65. DOI: 10.1056/NEJM200106283442601
- 3Zhang BC, Li WM, Xu YW, et al. High-dose statin pre-treatment for the prevention of contrast induced nephropathy: A Meta analysis. Can J Cardiol. 2011; 27: 851–8. DOI: 10.1016/j.cjca.2011.05.005
- 4Nash K, Hafeez A, Hou S, et al. Hospital acquired renal insufficiency. Am J Kidney Dis. 2002; 39: 930–6. DOI: 10.1053/ajkd.2002.32766
- 5Merten GJ, et al. Prevention of Contrast-Induced Nephropathy with Sodium Bicarbonate. JAMA. 2004; 291: 2328–34. DOI: 10.1001/jama.291.19.2328
- 6From AM, Bartholmai BJ, Williams AW, et al. Sodium Bicarbonate is associated with an increased incidence of Conrast Nephropathy: A retrospective study. Clin J AmSocNephrol. 2008; 3: 10–18. DOI: 10.2215/CJN.03100707
- 7Marenzi G, Assanelli E, Marana I, et al. N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty. NEJM. 2006; 354: 2773–82. DOI: 10.1056/NEJMoa054209
- 8Stone GW, McCullough PA, Tumlin JA, et al. CONTRAST Investigators. Fenoldopammesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA. 2003; 290: 2284–91. DOI: 10.1001/jama.290.17.2284
- 9Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003; 349: 1333–40. DOI: 10.1056/NEJMoa023204
- 10Barbieri L, Verdoia M, Schaffer A, et al. The role of statins in the prevention of contrast induced nephropathy: A meta-analysis of 8 randomized trials. J Thromb Thrombolysis. November 2014; 38(4): 493–502. DOI: 10.1007/s11239-014-1076-3
- 11Leoncini M, Toso A, Maioli M, et al. Early high-dose Rosuvastatin for contrast induced nephropathy prevention in acute coronary syndrome. J Am CollCardiol. 2014; 63: 71–9. DOI: 10.1016/j.jacc.2013.04.105
- 12Yoshida S, Kamihata H, Nakamura S, et al. Prevention of contrast induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol. 2009; 54: 192–8. DOI: 10.1016/j.jjcc.2009.05.006
- 13Kandula P, Shah R, Singh N, et al. Statins for prevention of contrast induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology. 2010; 15: 165–70. DOI: 10.1111/j.1440-1797.2009.01204.x
- 14Miki H, Okada Y, Hirokawa, N, et al. Analysis of the kinesin superfamily: Insights into structure and function. Trends Cell Biol. 2005; 15: 467–76. DOI: 10.1016/j.tcb.2005.07.006
- 15Morrison AC, Bare LA, Chambless LE, et al. Prediction of coronary heart disease risk using a genetic risk score: The Atherosclerosis Risk in Communities study. Am J Epidemiol. 2007; 166: 28–35. DOI: 10.1093/aje/kwm060
- 16Shiffman D, O’Meara ES, Bare LA, et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arteriosclerosis, thrombosis, and vascularbiology. 2008; 28: 173–9. DOI: 10.1161/ATVBAHA.107.153981
- 17Shiffman D, Chasman DI, Zee RYL, et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women’s Health Study. Journal of the American College of Cardiology. 2008; 51: 444–8. DOI: 10.1016/j.jacc.2007.09.044
- 18Hopewell JC, Parish S, Clarke R, et al. MRC/BHF Heart Protection Study Collaborative Group. No impact of KIF 6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J Am Coll Cardiol. 17 May 2011; 57(20): 2000–7.
- 19Seiler S, Kirchner J, Horn C, et al. Cargo binding and regulatory sites in the tail of fungal conventional kinesin. Nat. Cell Biol. 2000; 2: 333–8. DOI: 10.1038/35014022
- 20Davani S, Gozalo C, Gambert S, et al. The polymorphism Trp719Arg in the kinesin-like protein 6 is associated with the presence of late outgrowth endothelial progenitor cells in acute myocardial infarction. Atherosclerosis. 2010; 210: 48–50. DOI: 10.1016/j.atherosclerosis.2009.11.041
- 21Shiffman D, O’Meara ES, Rowland CM, et al. The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study. BMC Cardiovasc. Disord. 2011; 11: 10. DOI: 10.1186/1471-2261-11-10
- 22Iakoubova OA, Tong CH, Rowland CM, et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: The CARE and WOSCOPS trials. J Am Coll Cardiol. 2008, 51: 435–43. DOI: 10.1016/j.jacc.2007.05.057
- 23Shiffman D, Sabatine MS, Louie JZ, et al. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am J Cardiol. 2010; 105: 1300–5. DOI: 10.1016/j.amjcard.2009.12.049
- 24Ference BA, Yoo W, Flack JM, et al. A common KIF6 polymorphism increases vulnerability to low-density lipoprotein cholesterol: Two meta-analyses and a meta-regression analysis. PLoSOne. 2011; 6(12):
e28834 . DOI: 10.1371/journal.pone.0028834 - 25Peng P, Lian J, Huang RS, Xu L, et al. Meta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect. PLoS One. 2012; 7(12):
e5012 . DOI: 10.1371/journal.pone.0050126 - 26De Luca G, Dirksen MT, Spaulding C, et al. DESERT cooperation. Impact of diabetes on long-term outcome after primary angioplasty: Insights from the DESERT Cooperation. Diabetes Care. April 2013; 36(4): 1020–5. DOI: 10.2337/dc12-1507
- 27Navarese EP, Kubica J, Castriota F, et al. Safety and efficacy of biodegradable vs durable polymer drug-eluting stents: Evidence from a meta-analysis of randomized trials, EuroIntervention. 2011; 7: 985–94. DOI: 10.4244/EIJV7I8A155
- 28James MT, Gali WA, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010; 78: 803–9. DOI: 10.1038/ki.2010.258
- 29Barbieri L, Verdoia M, Schaffer A, et al. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. Nutr Metab Cardiovasc Dis. February 2015; 25(2): 181–6. DOI: 10.1016/j.numecd.2014.08.008
- 30Barbieri L, Verdoia M, Marino P, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. Eur J PrevCardiol. June 2016; 23(9): 931–7. DOI: 10.1177/2047487315614493
- 31Mehran R, Aymong E, Nikolsky E, et al. A simple risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention. J Am CollCardiol. 2004; 44: 1393–9. DOI: 10.1016/j.jacc.2004.06.068
- 32Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: Review focusing on prevention. J Am CollCardiol. 2004; 44: 1763–71. DOI: 10.1016/j.jacc.2004.06.075
- 33McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin. 2005; 21(2): 261–80. DOI: 10.1016/j.ccc.2004.12.003